FDA Clears Ultragenyx IND Application for UX016 to Treat Rare GNE Myopathy
Key Insights
The U.S. Food and Drug Administration has cleared Ultragenyx Pharmaceutical's Investigational New Drug application for UX016 (search), a sialic acid (search) prodrug designed to treat GNE myopathy (search).
GNE myopathy (search) is a rare, severely debilitating neuromuscular disease affecting approximately 10,000 people globally, with no currently approved therapy in the United States.
UX016 (search) is an investigational small-molecule prodrug that combines sialic acid (search) with a C16 fatty acid tail to improve biodistribution to muscle tissues.
Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for UX016 (search), a sialic acid (search) prodrug intended for the treatment of GNE myopathy (search). The clearance represents a significant milestone for patients with this rare genetic disorder, as it allows the company to initiate clinical trials evaluating the safety and efficacy of this novel therapeutic approach.
Understanding GNE Myopathy
GNE myopathy (search) (GNEM), also known as hereditary inclusion body myopathy (search) (HIBM) and Nonaka Myopathy (search), is a rare, severely debilitating, adult-onset autosomal recessive neuromuscular disease caused by a defect in the biosynthetic pathway for sialic acid (search) (SA). The condition is caused by mutations in the GNE gene (search), which disrupts sialic acid production critical for muscle function.
The body's inability to produce adequate SA leads to progressive muscle wasting and severe disability. Patients typically become non-ambulatory and ultimately dependent on caregivers for most activities of daily living due to loss of upper and lower extremity muscle function. GNEM is estimated to affect approximately 10,000 people in commercially accessible geographies, and there is currently no approved therapy in the United States.
UX016: A Novel Therapeutic Approach
UX016 (search) is an investigational small-molecule prodrug composed of sialic acid (search) (SA; also known as N‑acetylneuraminic acid [NANA]) and a C16 fatty acid tail designed to improve biodistribution to target tissues, like muscle, more effectively and efficiently than free SA. The compound is designed as an oral therapy to restore sialic acid levels in affected individuals.
By increasing SA availability in muscle, UX016 (search) is expected to restore sialylation of muscle glycoproteins and glycolipids and has the potential to slow or alter GNEM disease progression. In a GNEM (HIBM) mouse model, repeat subcutaneous administration of UX016 increased total, free and bound SA concentrations across multiple skeletal muscles and restored SA levels toward near normal.
Clinical Development Plans
With FDA approval of the IND application, Ultragenyx plans to proceed with clinical studies aimed at determining whether UX016 (search) can effectively address symptoms associated with GNE Myopathy (search) while maintaining a favorable safety profile. The company intends to initiate a Phase 1/2 clinical study to evaluate the safety, tolerability, and efficacy of UX016 in patients with this rare condition.
The FDA clearance enables the company to move forward with its clinical development program, though further details regarding trial timelines or participant recruitment have not yet been disclosed. This represents a critical step in bringing a potential treatment to patients who currently have no approved therapeutic options for their condition.